Ionis Pharmaceuticals, Inc.
IONSintermediaryIonis Pharmaceuticals is the leader in antisense technology, an approach that uses short strands of modified DNA to silence disease-causing genes at the RNA level. With Spinraza transforming SMA treatment and a rich pipeline of next-generation LICA platform drugs, Ionis is transitioning from a royalty-dependent model to a fully integrated rare disease company.
Produk & Pendapatan
Pangsa Pendapatan Produk
Komposisi Pendapatan ($1.8B)
Data statis (memuat keuangan langsung…)
Komposisi segmen dan pelanggan utama
Detail produk
Antisense therapy for spinal muscular atrophy, partnered with Biogen
Next-gen LICA antisense for hereditary ATTR polyneuropathy
Olezarsen (cardiovascular), donidalorsen (HAE), and CNS programs
Hubungan Rantai Pasok
Konteks makro dan pasar
GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집
GLP-1 시장 규모 (2030E)
mRNA 암백신 임상 성공률
AI 신약개발 단계
PFE/MRNA 52주 변화
Katalis mendatang
Berita terkini
Analisis AI
Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Ionis Pharmaceuticals, Inc..
Info Perusahaan
Gambaran umum sektor — 제약 / 바이오
Berita sektorGLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집
GLP-1 시장 규모 (2030E)
mRNA 암백신 임상 성공률
AI 신약개발 단계
PFE/MRNA 52주 변화
Tema utama
- •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
- •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
- •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성
Katalis mendatang
- ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
- ◆MRNA 암백신 FDA BLA 제출 예정